The FDA has approved Eli Lilly's injectable eczema treatment, Ebglyss (lebrikizumab), for use in adults and children aged 12 and older. The drug is expected to be available in the coming weeks.

The approval is based on 3 studies involving over 1,000 patients with moderate-to-severe eczema who had inadequate responses to topical or systemic treatments.

Last year, the FDA had delayed approval due to findings during the inspection of a contract manufacturer.

Lebrikizumab joins a range of existing eczema treatments, including AbbVie's Rinvoq, Pfizer's Cibinqo, and Sanofi-Regeneron's Dupixent, as well as generics such as cetirizine.

Ebglyss is a monoclonal antibody targeting the IL-13 protein, implicated in eczema progression. The drug is already approved in Europe and Japan, with additional markets anticipated this year.